Drug manufacturers Bristol Myers Squibb (BMS) and Merck are giving 340B covered entities refunds for overcharges on select products, according to public notices by the companies posted on the U.S. Health Resources and Services Administration (HRSA) website.
BMS
For the
…
340B Report held a webinar for its subscribers last week on Second Sight Solutions’ 340B ESP platform that administers drug manufacturers’ conditions on 340B pricing when covered entities use contract pharmacies. More than 800 subscribers registered to attend—a clear sign
…
Drug manufacturer Mallinckrodt’s SpecGx generic pharmaceutical subsidiary is providing refunds for 340B overcharges on 22 NDCs for purchases from Q3 2019 through Q2 2020.
This is the third time this month that a drug manufacturer has announced 340B refunds for
…
Drug manufacturers are asking Michigan state legislators to erase language in a new state law that Michigan hospitals say bars the companies from withholding 340B pricing if a covered entity refuses to hand over its contract pharmacy claims data, 340B
…
Drug manufacturer Amgen is providing refunds for overcharges during varying periods over three years on some of its top selling drugs including Enbrel ($4.8 billion in U.S. sales in 2020), Neulasta ($2 billion), Kyprolis ($710 million), Aranesp ($629 million), Epogen
…
America’s oldest consumer protection group, shunned by some former allies in the labor movement for alleged favoritism toward its corporate donor Amazon, has slammed the 340B program in a commentary for the conservative-leaning news and opinion website RealClearHealth.
“Sadly, as
…
Drug manufacturer AstraZeneca effective June 1 will stop offering voluntary 340B pricing on its orphan drugs to critical access hospitals, sole community hospitals, rural referral centers, and free-standing cancer hospitals, the company said yesterday.
“AstraZeneca is making this change to
…
Drug manufacturer Merck today extended its restrictions on 340B pricing involving contract pharmacies to community health centers. The restrictions have applied only to hospital covered entities until now.
Other grantee covered entities remain exempt “at this time,” Merck said, adding
…
340B Report, an independent news organization covering the 340B drug pricing program, is holding its first event—a May 18 webinar about implementing drug manufacturers’ controversial new rules on 340B contract pharmacies. It is an exclusive and free
…*Sign up for news summaries and alerts from 340B Report